Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

MBIO - Mustang Bio Inc Stock Price, Fair Value and News

$1.62-0.05 (-2.99%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

MBIO Price Action

Last 7 days

6.3%

Last 30 days

1.8%

Last 90 days

60%

Trailing 12 Months

-84.9%

MBIO RSI Chart

2025FebMarAprMayJunJulAugSep0102030405060708090

MBIO Valuation

Market Cap

6.7M

Price/Earnings (Trailing)

-2.05

Price/Sales (Trailing)

15.37

Price/Free Cashflow

-1.04

MBIO Price/Sales (Trailing)

20222023202420250100200300400500

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MBIO Fundamentals

MBIO Revenue

Revenue (TTM)

437.0K

Rev. Growth (Yr)

-60.83%

20182020202220240500K1M1.5M2M

MBIO Earnings

Earnings (TTM)

-3.3M

Earnings Growth (Yr)

90.71%

Earnings Growth (Qtr)

-398.04%

2018202020222024-80M-60M-40M-20M0

MBIO Profitability

Return on Equity

-113.31%

Return on Assets

-25.12%

Free Cashflow Yield

-96.52%

MBIO Investor Care

Shares Dilution (1Y)

800.45%

Diluted EPS (TTM)

-2.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250437.0K00
2024766.3K615.5K464.8K314.0K
20231.8M2.1M1.6M917.0K
2022367.0K310.0K894.0K1.4M
2021579.0K522.0K435.0K0
20201.4M1.1M885.0K708.0K
2019575.0K815.0K1.1M1.3M
2018560.5K573.5K567.5K569.0K
2017138.1K260.3K382.4K504.5K
201600016.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Mustang Bio Inc

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
 CEO
 WEBSITEmustangbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES113

Mustang Bio Inc Frequently Asked Questions

What is the ticker symbol for Mustang Bio Inc? What does MBIO stand for in stocks?

MBIO is the stock ticker symbol of Mustang Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mustang Bio Inc (MBIO)?

As of Fri Sep 19 2025, market cap of Mustang Bio Inc is 6.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MBIO stock?

You can check MBIO's fair value in chart for subscribers.

Is Mustang Bio Inc a good stock to buy?

The fair value guage provides a quick view whether MBIO is over valued or under valued. Whether Mustang Bio Inc is cheap or expensive depends on the assumptions which impact Mustang Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MBIO.

What is Mustang Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Sep 19 2025, MBIO's PE ratio (Price to Earnings) is -2.05 and Price to Sales (PS) ratio is 15.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MBIO PE ratio will change depending on the future growth rate expectations of investors.